Effects of Fermented Dairy Products on Defecation Changes Through Gut Microbiota

NCT ID: NCT06862310

Last Updated: 2025-03-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-09
• Study Completion Date: 2022-09-15

Brief Summary

The investigators recruited participants aged 20-65 years who did not have gastrointestinal diseases and who were not taking medication for digestive symptoms (e.g., gastric acid inhibitors, antibiotics, sterilization medications, or antidiarrheal agents) in the month before enrollment. The participants were prohibited from consuming any probiotic foods, supplements, or fermented dairy products except those that were provided during the 6-week study. Each participant first completed a 2-week adaptation period (n = 22). Subsequently, each participant was randomly assigned to either a control or intervention group. The participants received two 200-g daily servings of either a probiotic-infused fermented milk or a control dairy product for 4 weeks.

Detailed Description

This single-center, double-blind, parallel-design clinical trial assessed the impact of a probiotics-containing fermented milk consumed daily for 4 weeks on defecation patterns and the composition of the gut microbiome in healthy adults. We recruited participants aged 20-65 years who did not have gastrointestinal diseases and who were not taking medication for digestive symptoms (e.g., gastric acid inhibitors, antibiotics, sterilization medications, or antidiarrheal agents) in the month before enrollment. The participants were prohibited from consuming any probiotic foods, supplements, or fermented dairy products except those that were provided during the 6-week study. Each participant first completed a 2-week adaptation period (n = 22). Subsequently, each participant was randomly assigned to either a control or intervention group. The participants received two 200-g daily servings of either a probiotic-infused fermented milk or a control dairy product for 4 weeks. The intervention product contained 2 × 109 colony-forming units (CFU)/mL of Lactobacillus acidophilus and Bifidobacterium lactis, along with two starter cultures of Streptococcus thermophilus and L. bulgaricus. The intervention group was administered a median daily probiotics dose of 3 × 108 CFU (95% confidence interval [CI]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day). A written consent was obtained from each participant prior to the initiation of this study. The randomized controlled trial protocol was approved by the Joint Institutional Review Board of Taipei Medical University, Taiwan (N202101006 and N202110014).

Baseline Characteristics and Food Records Anthropometric and blood measurement data were collected at baseline and after 4 weeks of intervention. These included body weight, height, body mass index, lipid profile, and levels of liver function markers. Three-day food records (two weekdays and one weekend day) were collected at baseline and during each of the 4 weeks of intervention to monitor the participants' dietary habits.

Defecation frequency and constipation symptoms Since the selected subjects were healthy individuals, defecation frequency per week and Bristol Stool Scale scores were assessed using a questionnaire given to the participants.

Fecal Microbiota Analysis Fecal samples were collected at baseline and after the intervention. We used selective media, prepared as described elsewhere, to analyze the concentrations of Bifidobacterium spp., Lactobacillus spp., C. perfringens, and coliform organisms in the fecal samples. Five participants were randomly selected from each group, and their microbiome compositions were analyzed using 16S rRNA sequencing. Briefly, bacterial genomic DNA was isolated from the participants' stool samples using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, Germany), and the V3-V4 region of bacterial 16S rRNA genes was amplified using universal primers (341F and 805R). Demultiplexed paired reads were processed using Cutadapt software, v1.12 (DOI:10.14806/ej.17.1.200), and the filtered reads were analyzed using the DADA2 package, v1.3.5, in R software, v3.3.3, following the workflow proposed by Callahan et al. but without rarefying.

Conditions

Defecation Irregularity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: TRIPLE

Study Groups

placebo

acidified milk without adding beneficial bacteria

Group Type: PLACEBO_COMPARATOR

yogurt intervention

Intervention Type: OTHER

daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)

yogurt intervention

probiotic-enriched fermented milk (2.0 × 10⁹ Colony-forming unit \[CFU\]/mL)

Group Type: EXPERIMENTAL

yogurt intervention

Intervention Type: OTHER

daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)

Interventions

yogurt intervention

daily probiotics dose of 3 × 108 CFU (95% confidence interval \[CI\]: 1 × 109 to 3 × 1010 CFU) in 112 mL of fermented milk per day (95% CI: 100-187.5 mL/day)

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• aged 20-65 years old
• without gastrointestinal diseases or other health problems
• agree not to consume antibiotics, health supplements that may affect the composition of intestinal flora (ex. probiotics, prebiotics), and fermented dairy products (ex. yogurt, cheese other than those provided in this experiment) during the experiment.

Exclusion Criteria

• under pregnancy
• with gastrointestinal diseases or other health problems

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Z-Plus Biotechnology Co., Ltd.

UNKNOWN

Sponsor Role: collaborator

Taipei Medical University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Taipei Medical University

Taipei, , Taiwan

Countries

Taiwan

Other Identifiers

A-109-082

Identifier Type: OTHER

Identifier Source: secondary_id

lin5611_1

Identifier Type: -

Identifier Source: org_study_id